Lyseng-Williamson, Katherine A.
Article History
First Online: 7 August 2018
Change Date: 4 January 2019
Change Type: Correction
Change Date: 4 January 2019
Change Type: Correction
Change Type: Correction
Change Type: Correction
Change Type: Correction
Change Type: Correction
Change Details: The article Cabozantinib as first-line treatment in advanced renal cell carcinoma: a profile of its use, written by Katherine A. Lyseng-Williamson, was originally published Online First without open access.
Change Details: The article Cabozantinib as first-line treatment in advanced renal cell carcinoma: a profile of its use, written by Katherine A. Lyseng-Williamson, was originally published Online First without open access.
Change Date: 4 January 2019
Change Details: The article Cabozantinib as first-line treatment in advanced renal cell carcinoma: a profile of its use, written by Katherine A. Lyseng-Williamson, was originally published Online First without open access.
Change Details: The article Cabozantinib as first-line treatment in advanced renal cell carcinoma: a profile of its use, written by Katherine A. Lyseng-Williamson, was originally published Online First without open access.
Change Details: The article Cabozantinib as first-line treatment in advanced renal cell carcinoma: a profile of its use, written by Katherine A. Lyseng-Williamson, was originally published Online First without open access.
Change Details: The article Cabozantinib as first-line treatment in advanced renal cell carcinoma: a profile of its use, written by Katherine A. Lyseng-Williamson, was originally published Online First without open access.
Change Date: 4 January 2019
Change Date: 4 January 2019
Change Date: 4 January 2019
Compliance with ethical standards
:
: The preparation of this review was not supported by any external funding.
: K. A. Lyseng-Williamson is an employee of Adis/Springer, is responsible for the article content and declares no conflicts of interest.